What is claimed is:

1. Use of a nerve regenerating or nerve degeneration attenuating amount of phosphatase and tensin homolog (PTEN) lipid phosphatase inhibiting peptide in the manufacture of a medicament for ~~A method of~~ treating spinal cord injury comprising ~~-~~regenerating nerve or attenuating degeneration of nerve at a site of nerve injury wherein the medicament is to be administered ~~comprising administering~~ at or an area near an injured nerve~~, a nerve regenerating or nerve degeneration attenuating amount of phosphatase and tensin homolog (PTEN) lipid phosphatase inhibiting peptide~~.

~~2. The method according to claim 1~~, wherein the PTEN inhibitor peptide is modified PTEN peptide or fragment thereof in which phosphorylation site is modified such that a serine ~~or threonine~~ in the phosphorylation site is phosphorylated.

2. The use according to claim 1, wherein the phosphorylated serine is located at position Ser-380 and Ser-385.

3. The use according to claim 1, wherein the phosphorylated serine is located at position Ser-380, Ser-385 and Ser-370.

4. The use according to claim 1, wherein the phosphorylated serine is located at position Ser-380, Ser-385 and/or Ser-370.

~~3. The method according to claim 1, wherein the phosphorylated serine or threonine is located at position Thr-366, Ser-370, Ser-380, Thr-382, Thr-383 or Ser-385.~~

~~4. The method according to claim 1, wherein the phosphorylated serine or threonine is located at position Ser-370, Ser-380 and/or Ser-385.~~

~~5. The method according to claim 3, wherein the phosphorylated serine or threonine is located at position Ser-370, Ser-380 and Ser-385.~~

~~6. The method according to claim 3, wherein the phosphorylated serine or threonine is located at position Ser-380 and Ser-385.~~

5. The use according to claim 1, wherein the peptide comprises an amino acid sequence of SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5 or SEQ ID NO: 6.

6~~7~~. The use~~method~~ according to claims 1 to 5, wherein the peptide is a fragment of a peptide of phosphorylation site and/or PDZ domain binding motif.

7~~8~~. The use~~method~~ according to claims 1 to 6, wherein the peptide further comprises a peptide transfer domain (PTD).

8~~9~~. The use~~method~~ according to claims 1 to 7, wherein the nerve injury is in the central nervous system.

9~~10~~. Use of a nerve regenerating or nerve degeneration attenuating amount of phosphatase and tensin homolog (PTEN) lipid phosphatase inhibiting peptide in the manufacture of a medicament for ~~A method of~~ treating a condition associated with or caused by spinal cord injury comprising regenerating nerve or attenuating degeneration of nerve at a site of nerve injury ~~comprising~~ wherein the medicament is to be administered~~ing~~ at or an area near an injured nerve~~, a nerve regenerating or nerve degeneration attenuating amount of phosphatase and tensin homolog (PTEN) lipid phosphatase inhibiting peptide.~~, wherein the PTEN inhibitor peptide is modified PTEN peptide or fragment thereof in which phosphorylation site is modified such that a serine in the phosphorylation site is phosphorylated.

10~~11~~. The use~~method~~ of claim 9~~10~~, wherein the condition is neurogenic bladder.

11~~12~~. The use~~method~~ of claims 9 and 10~~11~~, wherein the condition is loss motor function.

12~~13~~. The use~~method~~ of claims 9 to 11~~11~~, wherein the condition is loss of movement coordination.